Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $87.8 million.

  • Anika Therapeutics' Non-Current Assets fell 781.96% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year decrease of 1485.64%. This contributed to the annual value of $89.1 million for FY2024, which is 1699.08% down from last year.
  • Anika Therapeutics' Non-Current Assets amounted to $87.8 million in Q3 2025, which was down 781.96% from $88.4 million recorded in Q2 2025.
  • Anika Therapeutics' Non-Current Assets' 5-year high stood at $188.8 million during Q1 2021, with a 5-year trough of $87.8 million in Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $176.7 million (2023), whereas its average is $145.2 million.
  • As far as peak fluctuations go, Anika Therapeutics' Non-Current Assets skyrocketed by 103.21% in 2023, and later plummeted by 4439.32% in 2024.
  • Anika Therapeutics' Non-Current Assets (Quarter) stood at $179.0 million in 2021, then increased by 0.32% to $179.6 million in 2022, then tumbled by 40.24% to $107.3 million in 2023, then fell by 16.99% to $89.1 million in 2024, then fell by 1.39% to $87.8 million in 2025.
  • Its Non-Current Assets was $87.8 million in Q3 2025, compared to $88.4 million in Q2 2025 and $88.1 million in Q1 2025.